

Mandar S Jog

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1203607/publications.pdf>

Version: 2024-02-01

130
papers

2,686
citations

257357

24
h-index

233338

45
g-index

131
all docs

131
docs citations

131
times ranked

3314
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	4.5	312
2	An update on the diagnosis and treatment of Parkinson disease. <i>Cmaj</i> , 2016, 188, 1157-1165.	0.9	286
3	Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study. <i>Movement Disorders</i> , 2002, 17, 1318-1320.	2.2	168
4	Supplement 4: Canadian Guidelines on Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, S1-S30.	0.3	103
5	Spinal Cord Stimulation Therapy for Gait Dysfunction in Advanced Parkinson's Disease Patients. <i>Movement Disorders</i> , 2018, 33, 783-792.	2.2	84
6	Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1735-1742.	2.2	76
7	Towards remote monitoring of Parkinson's disease tremor using wearable motion capture systems. <i>Journal of the Neurological Sciences</i> , 2018, 384, 38-45.	0.3	76
8	Loudness perception and speech intensity control in Parkinson's disease. <i>Journal of Communication Disorders</i> , 2014, 51, 1-12.	0.8	54
9	Gum chewing improves swallow frequency and latency in Parkinson patients. <i>Neurology</i> , 2010, 74, 1198-1202.	1.5	47
10	Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. <i>PLoS ONE</i> , 2017, 12, e0178670.	1.1	45
11	Auto detection and segmentation of physical activities during a Timed-Up-and-Go (TUG) task in healthy older adults using multiple inertial sensors. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2015, 12, 36.	2.4	44
12	Muscle Tone Physiology and Abnormalities. <i>Toxins</i> , 2021, 13, 282.	1.5	42
13	Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias. <i>Brain Research Bulletin</i> , 2006, 69, 512-518.	1.4	35
14	Effectiveness of BoNT A in Parkinson's Disease Upper Limb Tremor Management. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 663-669.	0.3	35
15	The Striatum and Subthalamic Nucleus as Independent and Collaborative Structures in Motor Control. <i>Frontiers in Systems Neuroscience</i> , 2016, 10, 17.	1.2	35
16	Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 5, 348.	1.1	35
17	Causes for Treatment Delays in Dystonia and Hemifacial Spasm: A Canadian Survey. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 704-711.	0.3	32
18	Non-invasive Transcranial Electrical Stimulation in Movement Disorders. <i>Frontiers in Neuroscience</i> , 2020, 14, 522.	1.4	32

#	ARTICLE	IF	CITATIONS
19	Spike source localization with tetrodes. <i>Journal of Neuroscience Methods</i> , 2005, 142, 305-315.	1.3	31
20	Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns – A New Future. <i>PLoS ONE</i> , 2016, 11, e0153739.	1.1	31
21	Quantification of whole-body bradykinesia in Parkinson's disease participants using multiple inertial sensors. <i>Journal of the Neurological Sciences</i> , 2018, 387, 157-165.	0.3	31
22	Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease. <i>Brain Research Bulletin</i> , 2007, 74, 66-74.	1.4	29
23	Examining the relationship between speech intensity and self-rated communicative effectiveness in individuals with Parkinson's disease and hypophonia. <i>Journal of Communication Disorders</i> , 2015, 56, 103-112.	0.8	28
24	Evaluation of Speech Amplification Devices in Parkinson's Disease. <i>American Journal of Speech-Language Pathology</i> , 2016, 25, 29-45.	0.9	28
25	Using Wearable Technology to Generate Objective Parkinson's Disease Dyskinesia Severity Score: Possibilities for Home Monitoring. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2017, 25, 1853-1863.	2.7	28
26	Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 6, 355.	1.1	27
27	Botulinum Toxin Induced Atrophy: An Uncharted Territory. <i>Toxins</i> , 2018, 10, 313.	1.5	26
28	Levodopa-induced dyskinesias detection based on the complexity of involuntary movements. <i>Journal of Neuroscience Methods</i> , 2010, 186, 81-89.	1.3	25
29	Characterization of multi-joint upper limb movements in a single task to assess bradykinesia. <i>Journal of the Neurological Sciences</i> , 2016, 368, 337-342.	0.3	25
30	Voice quality severity and responsiveness to levodopa in Parkinson's disease. <i>Journal of Communication Disorders</i> , 2018, 76, 1-10.	0.8	24
31	Wireless inertial measurement unit with GPS (WIMU-GPS) — Wearable monitoring platform for ecological assessment of lifespace and mobility in aging and disease. , 2011, 2011, 5815-9.		23
32	Using Ecological Whole Body Kinematics to Evaluate Effects of Medication Adjustment in Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 617-627.	1.5	23
33	Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 348.	1.1	23
34	Building spike representation in tetrodes. <i>Journal of Neuroscience Methods</i> , 2006, 157, 364-373.	1.3	22
35	PHTNet: Characterization and Deep Mining of Involuntary Pathological Hand Tremor using Recurrent Neural Network Models. <i>Scientific Reports</i> , 2020, 10, 2195.	1.6	21
36	Comparing GPS-Based Community Mobility Measures with Self-report Assessments in Older Adults with Parkinson's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 2361-2370.	1.7	21

#	ARTICLE	IF	CITATIONS
37	The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease. <i>Experimental Brain Research</i> , 2007, 176, 465-475.	0.7	20
38	Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 11-22.	0.3	20
39	Computing spike directivity with tetrodes. <i>Journal of Neuroscience Methods</i> , 2005, 149, 57-63.	1.3	19
40	Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review. <i>Gerontology</i> , 2016, 62, 371-380.	1.4	19
41	Manganese and Movement Disorders: A Review. <i>Journal of Movement Disorders</i> , 2021, 14, 93-102.	0.7	19
42	Parkinson's Disease, <i>NOTCH3</i> Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	2.2	18
43	Capturing whole-body mobility of patients with Parkinson disease using inertial motion sensors: Expected challenges and rewards. , 2011, 2011, 5833-8.		17
44	Neurotrophic factor expression in expandable cell populations from brain samples in living patients with Parkinson's disease. <i>FASEB Journal</i> , 2013, 27, 4157-4168.	0.2	17
45	Comparing movement patterns associated with Huntington's chorea and Parkinson's dyskinesia. <i>Experimental Brain Research</i> , 2012, 218, 639-654.	0.7	16
46	Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance. <i>Journal of Neurology</i> , 2018, 265, 1269-1278.	1.8	16
47	Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics. <i>Frontiers in Neurology</i> , 2020, 11, 599384.	1.1	16
48	Botulinum toxin in the treatment of lingual movement disorders. <i>Movement Disorders</i> , 2009, 24, 2199-2202.	2.2	15
49	Deep Brain Stimulation of the Subthalamic Nucleus Parameter Optimization for Vowel Acoustics and Speech Intelligibility in Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 510-524.	0.7	15
50	Long-term update of the effect of spinal cord stimulation in advanced Parkinson's disease patients. <i>Brain Stimulation</i> , 2020, 13, 1196-1197.	0.7	15
51	A deep explainable artificial intelligent framework for neurological disorders discrimination. <i>Scientific Reports</i> , 2021, 11, 9630.	1.6	15
52	Effect of Levodopa on Speech Dysfluency in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 150-154.	0.8	14
53	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.	1.7	14
54	Palliative Care Discussions in Multiple System Atrophy: A Retrospective Review. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 276-282.	0.3	13

#	ARTICLE	IF	CITATIONS
55	Personalized Bilateral Upper Limb Essential Tremor Therapy with Botulinum Toxin Using Kinematics. <i>Toxins</i> , 2019, 11, 125.	1.5	13
56	Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease. <i>Frontiers in Neurology</i> , 2018, 9, 260.	1.1	12
57	Zona incerta deep-brain stimulation in orthostatic tremor: efficacy and mechanism of improvement. <i>Journal of Neurology</i> , 2019, 266, 2829-2837.	1.8	12
58	Forward and backward walking in Parkinson disease: A factor analysis. <i>Gait and Posture</i> , 2019, 74, 14-19.	0.6	12
59	Methods for digital video recording, storage, and communication of movement disorders. <i>Movement Disorders</i> , 2001, 16, 1196-1200.	2.2	11
60	Self-Rated Communication-Related Quality of Life of Individuals With Oromandibular Dystonia Receiving Botulinum Toxin Injections. <i>American Journal of Speech-Language Pathology</i> , 2017, 26, 674-681.	0.9	11
61	Expanding the search for genetic biomarkers of Parkinson's disease into the living brain. <i>Neurobiology of Disease</i> , 2020, 140, 104872.	2.1	11
62	Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor – the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 61.	1.1	11
63	Dynamic Decomposition of Motion in Essential and Parkinsonian Tremor. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 116-124.	0.3	10
64	Effect of concurrent walking and interlocutor distance on conversational speech intensity and rate in Parkinson's disease. <i>Gait and Posture</i> , 2016, 43, 132-136.	0.6	9
65	Standardized algorithm for muscle selection and dosing of botulinum toxin for Parkinson tremor using kinematic analysis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642095408.	1.5	9
66	Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review. <i>Toxins</i> , 2020, 12, 470.	1.5	9
67	Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Toxins</i> , 2020, 12, 807.	1.5	9
68	Mercury and Movement Disorders: The Toxic Legacy Continues. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 493-501.	0.3	9
69	Speech Intensity Response to Altered Intensity Feedback in Individuals With Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 2261-2275.	0.7	8
70	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	1.5	8
71	“Weight-holding tremor”: An unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , 1995, 10, 228-229.	2.2	7
72	A dynamical-systems model for Parkinson's disease. <i>Biological Cybernetics</i> , 2000, 83, 47-59.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Is there a tipping point in neuronal ensembles during learning?. Neuroscience Letters, 2007, 412, 39-44.	1.0	7
74	Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study. Clinical Neurology and Neurosurgery, 2016, 150, 117-124.	0.6	7
75	Pearls & Oysters: Spinocerebellar ataxia type 3 presenting with cervical dystonia without ataxia. Neurology, 2016, 86, e1-3.	1.5	7
76	Down the Stairs Dystoniaâ€”A Novel Taskâ€”Specific Focal Isolated Syndrome. Movement Disorders Clinical Practice, 2017, 4, 121-124.	0.8	7
77	Effects of Deep Brain Stimulation of the Subthalamic Nucleus Settings on Voice Quality, Intensity, and Prosody in Parkinsonâ€™s Disease: Preliminary Evidence for Speech Optimization. Canadian Journal of Neurological Sciences, 2019, 46, 287-294.	0.3	7
78	Intrapallidal injection of botulinum toxin A recovers gait deficits in a parkinsonian rodent model. Acta Physiologica, 2019, 226, e13230.	1.8	7
79	Managing autonomic dysfunction in Parkinsonâ€™s disease: a review of emerging drugs. Expert Opinion on Emerging Drugs, 2020, 25, 37-47.	1.0	7
80	Variation in Speech Intelligibility Ratings as a Function of Speech Rate Modification in Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2021, 64, 1773-1793.	0.7	7
81	Hemiparkinsonism-Somatic Hemiatrophy Syndrome. Canadian Journal of Neurological Sciences, 2002, 29, 184-187.	0.3	6
82	Variability of hand tremor in rest and in posture — A pilot study. , 2011, 2011, 470-3.		6
83	Pearls & Oysters: Niemann-Pick disease type C in a 65-year-old patient. Neurology, 2016, 87, e79-81.	1.5	6
84	Kinematic and kinetic assessment of upper limb movements in patients with writer's cramp. Journal of NeuroEngineering and Rehabilitation, 2016, 13, 15.	2.4	6
85	Teaching Video Neuro <i>Images:</i> Lithium-induced reversible Pisa syndrome. Neurology, 2017, 88, e184.	1.5	6
86	Botulinum toxin A injection into the entopeduncular nucleus improves dynamic locomotory parameters in hemiparkinsonian rats. PLoS ONE, 2019, 14, e0223450.	1.1	6
87	Changes in Cortical Excitability and Parkinson Tremor After Botulinum Toxin Therapy. Neurology, 2021, 97, .	1.5	6
88	Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease. Clinical Neurology and Neurosurgery, 2010, 112, 392-399.	0.6	5
89	Neurophysiology and neurochemistry of corticobasal syndrome. Journal of Neurology, 2018, 265, 991-998.	1.8	5
90	Indomethacinâ€”Responsive Idiopathic Red Ear Syndrome: Case Report and Pathophysiology. Headache, 2018, 58, 306-308.	1.8	5

#	ARTICLE	IF	CITATIONS
91	Developing a Consistent, Reproducible Botulinum Toxin Type A Dosing Method for Upper Limb Tremor by Kinematic Analysis. <i>Toxins</i> , 2021, 13, 264.	1.5	5
92	Minipolymyoclonus: A Critical Appraisal. <i>Journal of Movement Disorders</i> , 2021, 14, 114-118.	0.7	5
93	Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off. <i>Current Medical Research and Opinion</i> , 2008, 24, 3207-3215.	0.9	4
94	Spinal cord stimulation therapy for gait dysfunction in progressive supranuclear palsy patients. <i>Journal of Neurology</i> , 2021, 268, 989-996.	1.8	4
95	Musculoskeletal Model to Predict Muscle Activity During Upper Limb Movement. <i>IEEE Access</i> , 2021, 9, 111472-111485.	2.6	4
96	Speech Rate Mediated Vowel and Stop Voicing Distinctiveness in Parkinson's Disease. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 4096-4123.	0.7	4
97	Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy. <i>Tremor and Other Hyperkinetic Movements</i> , 2016, 6, 410.	1.1	4
98	Levodopa and Parkinson disease—electrophysiological perspectives in animal models. <i>Experimental Neurology</i> , 2011, 231, 11-13.	2.0	3
99	Transitioning from Unilateral to Bilateral Upper Limb Tremor Therapy for Parkinson's Disease and Essential Tremor Using Botulinum Toxin: Case Series. <i>Toxins</i> , 2018, 10, 394.	1.5	3
100	Spontaneous Intracranial Hypotension as a Cause of Exacerbation in Huntington's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 357-359.	0.3	3
101	Efficacy and Acceptance of a Lombard-response Device for Hypophonia in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 634-641.	0.3	3
102	Focal limb dystonia and tremor: Clinical update. <i>Toxicon</i> , 2020, 176, 10-14.	0.8	3
103	Spinal Cord Stimulation Therapy for Gait Dysfunction in Two Corticobasal Syndrome Patients. <i>Canadian Journal of Neurological Sciences</i> , 2021, 48, 278-280.	0.3	3
104	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 199-212.	0.8	3
105	Exploring the Psychosocial Impact of Botulinum Toxin Type A Injections for Individuals With Oromandibular Dystonia: A Qualitative Study of Patients' Experiences. <i>American Journal of Speech-Language Pathology</i> , 2021, 30, 1314-1328.	0.9	3
106	A Theoretical Information Processing-Based Approach to Basal Ganglia Function. <i>Advances in Behavioral Biology</i> , 2009, , 211-222.	0.2	3
107	Myoclonus-dystonia presentation of ATM gene mutation in a Canadian Mennonite. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 264-267.	0.8	3
108	Epilepsia partialis continua in relapsing-remitting multiple sclerosis: A possible distinct relapse phenotype. <i>Clinical Neurology and Neurosurgery</i> , 2022, 213, 107099.	0.6	3

#	ARTICLE	IF	CITATIONS
109	How Long Should GPS Recording Lengths Be to Capture the Community Mobility of An Older Clinical Population? A Parkinson's Example. <i>Sensors</i> , 2022, 22, 563.	2.1	3
110	Brain iron deposition and movement disorders in hereditary haemochromatosis without liver failure: A cross-sectional study. <i>European Journal of Neurology</i> , 2022, , .	1.7	3
111	Targeted copy number variant identification across the neurodegenerative disease spectrum. <i>Molecular Genetics & Genomic Medicine</i> , 0, , .	0.6	3
112	Sensory manipulation in writer's cramp: Possibilities for rehabilitation. , 2013, , .		2
113	Quantifying the short-term effects of deep brain stimulation surgery on bradykinesia in Parkinson's disease patients. , 2014, , .		2
114	Future Perspectives: Assessment Tools and Rehabilitation in the New Age. , 2017, , 155-182.		2
115	Can heterozygotes of autosomal recessive disorders have clinical manifestations?. <i>Movement Disorders</i> , 2018, 33, 1368-1369.	2.2	2
116	Tourette-Like Syndrome in a Patient with <i>RBFOX1</i> Deletion. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 86-88.	0.8	2
117	A Comparison of Speech Amplification and Personal Communication Devices for Hypophonia. <i>Journal of Speech, Language, and Hearing Research</i> , 2020, 63, 2695-2712.	0.7	2
118	Segmentation and detection of physical activities during a sitting task in Parkinson's disease participants using multiple inertial sensors. <i>Journal of Applied Biomedicine</i> , 2017, 15, 282-290.	0.6	1
119	Reply to: Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss. <i>Movement Disorders</i> , 2018, 33, 1829-1830.	2.2	1
120	Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 742-752.	0.3	1
121	“Cognitive freezing”: A newly recognized episodic phenomenon in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 49-54.	1.1	1
122	Role of Vitamins in Advanced therapy for Parkinson's disease: Decoding the paradox. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-7.	0.3	1
123	Expanding the Clinical Spectrum of RFC1 Gene Mutations. <i>Journal of Movement Disorders</i> , 2022, 15, 167-170.	0.7	1
124	Letter to the Editor Regarding “Statistical Shape Analysis of Subthalamic Nucleus in Patients with Parkinson's Disease”. <i>World Neurosurgery</i> , 2019, 128, 629.	0.7	0
125	Diagnosing Unusual Presentations of Dopa-Responsive Conditions: Thinking on your Feet. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 127-129.	0.3	0
126	Iron Chelation in Movement Disorders: Logical or Ironical. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-8.	0.3	0

#	ARTICLE	IF	CITATIONS
127	Optimizing the selection of Parkinson's disease patients for neuromodulation using the levodopa challenge test. <i>Journal of Neurology</i> , 2021, , 1.	1.8	0
128	Editorial on the Special Issue "Botulinum Toxin for the Treatment of Neurological Disorders: Where We Are and Where We Need to Go". <i>Toxins</i> , 2022, 14, 41.	1.5	0
129	Review: catechol O-methyl transferase inhibitors plus L-dopa and some surgical interventions improve Parkinson disease symptoms. <i>ACP Journal Club</i> , 2004, 140, 42.	0.1	0
130	Review: Catechol O-methyl transferase inhibitors plus L-dopa and some surgical interventions improve Parkinson disease symptoms. <i>ACP Journal Club</i> , 2004, 140, 42.	0.1	0